Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Regeneron Pharmaceuticals Inc REGN

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.


NDAQ:REGN - Post by User

Post by queueon Mar 01, 2002 5:28pm
173 Views
Post# 4831558

from money.com

from money.comhttps://money.cnn.com/2002/02/28/investing/propicks/ Lon Gerber, analysts with Thomson Financial/Lancer Analytics, keeps an eye on insider transactions and has a couple of suggestions based on insider buying. LON GERBER'S PICKS * Regeneron Pharmaceuticals (REGN) * Peregrine Systems (PRGN) "The one company that really stood out was Regeneron Pharmaceuticals. We had the chairman adding $75,000 shares back on February 7. He's been at Regeneron since 1995. He previously was the CEO over at Merck," Gerber said. "But what really sticks out in this example is his track record," he continued. "He's one of the most savvy traders that we follow. Specifically he's bought Regeneron shares 10 prior times in the past and in each of these instances the stock was higher six months later and the average gain is an amazing 120 percent." Gerber's second pick is Peregrine Systems. "This stock was trading at a three-year low and we had a group of four insiders combining to add 52,000 shares. Again, this was on February 17. So a very bullish sign of this company as well." Shares of Regeneron Pharmaceuticals (REGN: down $0.55 to $22.61, Research, Estimates) are in a 52-week range of $38.00 to $19.74.
Bullboard Posts